Early evaluation of the therapeutic effect of denosumab on tartrate-resistant acid phosphatase 5b expression in a giant cell tumor of bone: a case report

BMC Research Notes

Mitsuru Koizumi³  Teruko Ueno⁴  Noriko Motoi¹  Tabu Gokita²  Taisuke Tanizawa²  Keisuke Ae²  Takashi Shimoji²  Seiichi Matsumoto²  Naoto Watanabe² 

[1] Pathology, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan;Department of Orthopaedic Oncology, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan;Nuclear Medicine, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan;Radiology, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan

关键词: Tartrate-resistant acid phosphatase 5b;    Receptor activator of nuclear factor kappa-B ligand;    Giant cell tumor of bone;   

Others  :  1129822
DOI  :  10.1186/1756-0500-7-608

 received in 2014-04-27, accepted in 2014-09-01,  发布年份 2014

【 摘 要 】

Background

Giant cell tumor of bone is an osteolytic, usually benign, tumor characterized by the infiltration of osteoclast-like giant cells. The receptor activator of nuclear factor kappa-B ligand pathway has been shown to play a key role in the pathogenesis of giant cell tumor. Treatment for refractory, recurrent, or metastatic giant cell tumor remains challenging. A monoclonal antibody to receptor activator of nuclear factor kappa-B ligand, denosumab, offers promise in these patients. Tartrate-resistant acid phosphatase 5b, a bone resorption marker, is secreted from osteoclasts and this marker is reported to be high in patients with giant cell tumor of bone. We investigated the effects of denosumab and the usefulness of a tartrate-resistant acid phosphatase 5b as a monitoring marker in the management of a refractory giant cell tumor of bone.

Case presentation

A 41-year-old Japanese male with right ischiac pain was diagnosed with a giant cell tumor in his right ischium. Since the tumor extended to the acetabulum, there was a possibility that en bloc resection might significantly impair function of the hip joint and curettage could cause massive bleeding. Therefore, denosumab therapy (120 mg, administered 3 times every 4 weeks) was performed before radical surgery. The giant cell tumor of bone was treated with denosumab successfully. No adverse reaction was noted. Tartrate-resistant acid phosphatase 5b secretion was measured in the patient’s serum to monitor the response to denosumab, and a rapid normalization of the marker was observed after the first denosumab administration.

Conclusion

This case suggests that denosumab therapy might be an option for treating refractory giant cell tumor of bone, and that tartrate-resistant acid phosphatase 5b might be an early marker with which to monitor the efficacy of denosumab therapy for refractory giant cell tumor.

【 授权许可】

   
2014 Watanabe et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Kim Y, Nizami S, Goto H, Lee FY: Morden interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg 2012, 4:107-116.
• [2]Caudell JJ, Ballo MT, Zagars GK, Lewis VO, Weber KL, Lin PP, Marco RA, El-Naggar AK, Benjamin RS, Yasko AW: Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 2003, 57:158-165.
• [3]Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X: RANK (Receptor Activator of Nuclear Factor kappa B) and RANK Ligand Are Expressed in Giant Cell Tumors of Bone. Am J Clin Pathol 2002, 117:210-216.
• [4]Huang L, Xu J, Wood DJ, Zheng MH: Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-κB in giant cell tumour of bone: possible involvement in tumour cell-induced osteoclast-like cell formation. Am J Pathol 2000, 156:761-767.
• [5]Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S: Denosumab in patients with giant-cell tumour of bone: an open-label, phase II study. Lancet Oncol 2010, 11:275-280.
• [6]Shinozaki T, Saito K, Kobayashi T, Yanagawa T, Takagishi K: Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone. Open Orthop J 2012, 6:392-399.
• [7]Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisian MV, Kim W, Lee FY: Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 2005, 23:203-209.
• [8]Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK: Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 2006, 52:499-509.